



**AUSTRALIAN INSTITUTE FOR
MACHINE LEARNING**

MACHINE LEARNING

PRESENTATION

The Algorithm

Assoc Prof Johan Verjans MD PhD FESC FRACP

Lived and worked in

- 📍 Maastricht
- 📍 Philadelphia
- 📍 University of California
- 📍 Utrecht
- 📍 London
- 📍 Israel
- 📍 Boston



Cardiometabolic & Imaging Cardiologist
PI Cardiometabolic & AI Clinical Trials
Royal Adelaide Hospital / Jones Radiology

**Deputy Director (Medical),
Australian Institute for
Machine Learning AIML**
AUs Largest ML group (200+ people)
#6 in Computer Vision (csranks)
#7 AI (TIMES higher education)





Leadership

- Federal member, Dutch Medical Association
- National Chair, Dutch Cardiovascular Research (early-mid)
- Partner, National Data Flagship- Australian Cardiovascular Alliance
- Chair - Australian Society for Molecular Imaging
- Board Member - State AI advisory board (AI in Health Hub)
- CareMappr steering committee (Deploying Medicare Dashboard - Digital Health)
- Advisory boards Startups, AI/ML advisor GSK global

- Deputy Director (Health), Australian Institute for Machine Learning (AIML)

Clinical / Research

- 10+ years in Clinical Cardiology
- 10+ years in Clinical Trials
- 3+ years in AI Clinical Trials
- 15+ years in Molecular Biology / Cellular imaging / Molecular Imaging / Imaging / Metabolomics
- 10+ years Photonics Research
- 10+ Worked with state and federal governments
- Editorial Boards -
 - European Heart Journal - Digital Health
 - Frontiers in Cardiology

AI /ML

8+ years in AI/ML

- Building ML pipeline from idea-data-annotation-ML-implementation
- Cross-disciplinary and cross-institutional collaboration
- National AI Centre - AI Digital Capability Centre
- National AI in Health Centre 100M

Methods development

- Vision & Language
- Medical Visual Question Answering
- Causality / Reasoning
- Standardisation / Ethics

Clinical development

- Cardiovascular/GI Imaging
- Oncology
- Genomics/Lipidomics
- Pathology (Breast/Cell imaging)
- Multimodal analytics

Clinical Trials

- AI in Chest pain decision making
- Breath analysis



★ Top publications

Top cited publications over the last five years [Learn more](#)

| Publication | h5-index | h5-median |
|-------------------------------------------------------------------|----------|-----------|
| 1. Nature | 414 | 607 |
| 2. The New England Journal of Medicine | 410 | 704 |
| 3. Science | 391 | 564 |
| 4. IEEE/CVF Conference on Computer Vision and Pattern Recognition | 356 | 583 |
| 5. The Lancet | 345 | 600 |
| 6. Advanced Materials | 294 | 406 |
| 7. Cell | 288 | 459 |
| 8. Nature Communications | 287 | 389 |



28 papers in 2021

23 papers in 2022



ALGORITHM FACTORY



**A FACTORY THAT NEEDS
ALGORITHMS**




Projects ongoing

- Imaging
 - Cardiovascular Imaging
 - GI / Colonoscopy
 - Colorectal cancer
 - Chest CT / Xray
 - Orthopaedics
 - Ophthalmology
 - Critical Care
 - Breast Cancer
- Proteomics, Lipidomics, Metabolomics
- Lipidomics to predict cardiovascular disease and treatment response
 - Breath Analysis
- Genomics / Statewide Genomics Centre
- Clinical Trials / Drug Development / Testing
 - Treatment response Leukemia
 - Immunotherapy response




Clinical neuroimaging tools / ML tools (Dr Stephan Lau, Prof Mark Jenkinson)


Nomogram Uncertainty



Application of MRI tools to CT: ICV measurement for craniosynostosis



Laurence Vass, Nela Demeyere,
Sarah Pendlebury, Mark Jenkinson




Ludo Griffanti, Jelena Bozek,
Stephan Lau, Mark Jenkinson

Classification and Explanation of Diseases from Chest X-Ray Hermoza, Carneiro MICCAI'20]

Disease score


Disease localization (weak supervision)



Few-Shot Anomaly Detection for Polyp Frames from Colonoscopy

Yu Tian^{1,3} Gabriel Maicas¹ Leonardo Zorron Cheng Tao Pu^{2,4}
Rajvinder Singh² Johan W. Verjans^{2,3} Gustavo Carneiro¹


MyoSPOT: Myocardial Pathology Segmentation combining multisequence CMR (Zhang, Verjans, Xiao - MICCAI 2020 award)



Real-time Polyp Detection and Classification (w/ uncertainty) Carneiro et al. Media'20




Flowchart for algorithmic audit (Oakden-Rayner)



Top: Overview of Internal Audit Framework from Raji et al. Gray = a process, and colored sections represent documents. Orange = produced by the engineering and product teams, and green = jointly developed. Bottom: Proposed modifications for the Medical Algorithmic Audit

AI for Sliding Sign Detection to Diagnose Endometriosis. (G. Maicas, Carneiro, Hull, World Congress on Endometriosis 2021)




Improving Scaphoid Fracture Detection with Human Expert Annotation (Shen, Liao, Verjans - CHI 2021)



Answering open-ended questions Winner Medical VQA+VQG ImageCLEF (Liao, Verjans NIH ImageCLEF 2020)

VQA -> Image Classification





**Formal collaborations
after
government support
of AIML
>6M in grants
30+ projects**



Women's and Children's Hospital
ADELAIDE



2019

2020

2022



Member of Global Alliance of Centres AI in Medicine -
Monthly meetings (ACAIM)



Founding Centers



*Nominated AI Centre in Medicine of the Year
(AIMED 2022)*

APAS Petri Dish Reader

First in class FDA approved device



THE UNIVERSITY OF ADELAIDE
AUSTRALIAN INSTITUTE FOR MACHINE LEARNING

Clinical 3D Bladder Scanner

AI enabled



RapidX AI Chest pain

Cluster-randomised Clinical Trial



Australian Government
National Health and Medical Research Council

SIEMENS Healthineers


AI enabled Clinician Insights

using real-time medicare and hospital data



AI Breath Analysis


Clinical trial



OPTICAL FREQUENCY COMB

AI Leukemia detection

Clinical Cell Classification



Interpretable Deep Learning for Chronic Myelomonocytic Leukemia Analysis

One-stop-shop for companies

Leading Methods AI

Computer Scientists
Data Scientists etc

Leading Applied AI

Computer Scientists
Data Scientists, Molecular Scientists,
Clinicians

Best Datasets

South Australia Health Network is unique due to its size,
connected single health system
stable population

-> Best longitudinal clinical dataset in Australia



GlaxoSmithKline



CLINICAL AI PIPELINE



Data Collection

Collecting data from medical records, patient surveys, and other sources



AI Modeling

Building models to predict outcomes and suggest treatments



Data Cleaning

Organizing and preparing data for analysis



Deployment




Data Analysis

Using algorithms to identify patterns in the data



Audit

Medical AI requires a variety of technologies to be successful, from data collection to AI modeling.




**TRENDS
DIGITAL
BIOMARKERS**


Disease Diagnosis

Disease Progression

**Treatment Response /
Strategies**



GROWTH OPPORTUNITIES



NAVIGATING CHALLENGES IN NEW ERA

- **Access to Innovation**

Challenges in accessing innovation, which includes the discovery and development of new drugs and treatments.

- **Innovation by Few**

Small companies, or even one man can build competitive products in AI/ML space.

- **Personalised Medicine**

There is growing demand for personalized medicine.

- **Digital therapeutics**

The emergence of digital therapeutics presents new opportunities for pharmaceutical companies, but also poses challenges in developing and commercializing these treatments.

- **Drug cost**

The cost of developing new drugs is increasing, and pharmaceutical companies will have to find ways to reduce costs while still producing effective treatments.

- **Drug delivery**

The industry is moving towards non-traditional drug delivery methods, such as gene therapies and RNA-based drugs, which present unique challenges.

- **Aging population**

As the global population ages, pharmaceutical companies will have to develop treatments for age-related diseases, such as Alzheimer's and Parkinson's and ageing body in general.

- **Cybersecurity**

GSK will have to keep investing in robust cybersecurity measures to protect sensitive data.

- **Data privacy**

With the increasing amount of health data being generated, data privacy and security will be a critical concern for pharmaceutical companies.

- **Regulatory hurdles**

With the continually evolving landscape, GSK will need to remain agile and adaptable to stay compliant.

- **Environmental concerns**

The industry will have to address environmental concerns, such as the impact of drug manufacturing on the environment, and develop sustainable solutions.

- **Access to talent**

To get the best talent - GSK.AI must be considered on of the best places to work for Applied AI.

NAVIGATING PHARMA CHALLENGES IN NEW ERA

Making the right choices



**STANFORD SCIENTISTS PRETTY
MUCH CLONED OPENAI'S GPT FOR A
MEASLY \$600**



**AUSTRALIAN INSTITUTE FOR
MACHINE LEARNING**

MACHINE LEARNING

Thank you

Assoc Prof Johan Verjans MD PhD FESC FRACP

johan.verjans@adelaide.edu.au



THE UNIVERSITY
of ADELAIDE

www.adelaide.edu.au/aiml